Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Patients in the original HCMR cohort with:
1. Obstructive HCM
* Males and females between 18 and 65 years of age
* BMI < 35 kg/m2
* LVOT-G at entry as follows:
Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and <50 mmHg with post-Valsalva LVOT-G ≥50 mmHg
• NYHA Class II or III or
2. Non-obstructive HCM
* Same criteria as above except resting LVOT-G is <30mmHg and post-Valsalva gradient <50mm Hg
* BMI <40kg/m2
* Elevated NT-proBNP > 300 pg/mL at the time of enrollment
* LVEF ≥55%
Exclusion Criteria:
* Paroxysmal atrial fibrillation or flutter documented prior to entry.
* Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for >6 months.)
* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.
* Pregnancy due to potential risk of gadolinium to the fetus
* Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 09/22/2025. Questions regarding updates should be directed to the study team contact.